Regenerex Pharma (RGPX) Gains from Sales and Divestitures (2023 - 2025)

Regenerex Pharma (RGPX) has 3 years of Gains from Sales and Divestitures data on file, last reported at $10.6 million in Q3 2025.

• Gains from Sales and Divestitures for Q3 2025 came in at $10.6 million, up 265.1% year-over-year; the trailing twelve-month figure through Sep 2025 was $10.6 million (up 265.1% YoY), and the FY2025 annual result was $5.7 million, up 120.13% from the prior year.
• Gains from Sales and Divestitures rose to $10.6 million in Q3 2025 per RGPX's latest filing, from $5.9 million in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $10.6 million in Q3 2025 and troughed at $2.2 million in Q3 2023.
• A 3-year average of $4.6 million and a median of $2.9 million in 2024 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures soared 31.31% in 2024, then soared 265.1% in 2025.
• A 3-year view of Gains from Sales and Divestitures shows it stood at $2.4 million in 2023, then grew by 22.68% to $2.9 million in 2024, then soared by 265.1% to $10.6 million in 2025.
• Business Quant data shows RGPX's Gains from Sales and Divestitures at $10.6 million in Q3 2025, $5.9 million in Q2 2025, and $5.7 million in Q1 2025.